KRW 13130.0
(-3.95%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 49.56 Billion KRW | -32.38% |
2022 | 73.3 Billion KRW | 122.72% |
2021 | 32.91 Billion KRW | 62.08% |
2020 | 20.3 Billion KRW | -55.15% |
2019 | 45.28 Billion KRW | 0.0% |
2018 | - KRW | -100.0% |
2017 | 27 Billion KRW | 1250.0% |
2016 | 2 Billion KRW | 0.0% |
2015 | - KRW | -100.0% |
2014 | 8 Billion KRW | 0.0% |
2013 | - KRW | -100.0% |
2012 | 7 Billion KRW | 0.0% |
2011 | - KRW | -100.0% |
2010 | 10 Billion KRW | 20.63% |
2009 | 8.29 Billion KRW | -47.76% |
2008 | 15.87 Billion KRW | 0.0% |
2007 | - KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 65.83 Billion KRW | -14.56% |
2024 Q1 | 77.04 Billion KRW | 55.43% |
2023 FY | 49.56 Billion KRW | -32.38% |
2023 Q1 | 47.08 Billion KRW | -35.77% |
2023 Q4 | 49.56 Billion KRW | -28.75% |
2023 Q3 | 69.56 Billion KRW | 23.78% |
2023 Q2 | 56.2 Billion KRW | 19.36% |
2022 Q2 | 50.11 Billion KRW | -17.6% |
2022 Q4 | 73.3 Billion KRW | 26.23% |
2022 Q3 | 58.07 Billion KRW | 15.88% |
2022 Q1 | 60.81 Billion KRW | 84.78% |
2022 FY | 73.3 Billion KRW | 122.72% |
2021 Q3 | 47.68 Billion KRW | 1.92% |
2021 FY | 32.91 Billion KRW | 62.08% |
2021 Q4 | 32.91 Billion KRW | -30.97% |
2021 Q1 | 20.26 Billion KRW | -0.2% |
2021 Q2 | 46.78 Billion KRW | 130.84% |
2020 Q4 | 20.3 Billion KRW | -52.67% |
2020 Q1 | 45.99 Billion KRW | 1.58% |
2020 Q2 | 46.88 Billion KRW | 1.92% |
2020 Q3 | 42.9 Billion KRW | -8.48% |
2020 FY | 20.3 Billion KRW | -55.15% |
2019 FY | 45.28 Billion KRW | 0.0% |
2019 Q4 | 45.28 Billion KRW | 151.7% |
2019 Q2 | 61.06 Million KRW | -47.39% |
2019 Q1 | 116.07 Million KRW | 0.0% |
2019 Q3 | 17.99 Billion KRW | 29360.05% |
2018 Q3 | - KRW | -100.0% |
2018 FY | - KRW | -100.0% |
2018 Q1 | 27 Billion KRW | 0.0% |
2018 Q2 | 2 Billion KRW | -92.59% |
2018 Q4 | - KRW | 0.0% |
2017 Q3 | 27 Billion KRW | 0.0% |
2017 FY | 27 Billion KRW | 1250.0% |
2017 Q1 | 2 Billion KRW | 0.0% |
2017 Q4 | 27 Billion KRW | 0.0% |
2017 Q2 | 27 Billion KRW | 1250.0% |
2016 FY | 2 Billion KRW | 0.0% |
2016 Q4 | 2 Billion KRW | 0.0% |
2016 Q3 | 2 Billion KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q1 | - KRW | 0.0% |
2015 Q3 | 2 Billion KRW | -90.24% |
2015 Q1 | 8 Billion KRW | 0.0% |
2015 Q2 | 20.5 Billion KRW | 156.25% |
2015 FY | - KRW | -100.0% |
2015 Q4 | - KRW | -100.0% |
2014 Q2 | 2 Billion KRW | 0.0% |
2014 Q1 | 2 Billion KRW | 0.0% |
2014 FY | 8 Billion KRW | 0.0% |
2014 Q4 | 8 Billion KRW | 300.0% |
2014 Q3 | 2 Billion KRW | 0.0% |
2013 Q1 | 7 Billion KRW | 0.0% |
2013 FY | - KRW | -100.0% |
2013 Q3 | 7 Billion KRW | 0.0% |
2013 Q2 | 7 Billion KRW | 0.0% |
2013 Q4 | - KRW | -100.0% |
2012 Q4 | 7 Billion KRW | 0.0% |
2012 FY | 7 Billion KRW | 0.0% |
2012 Q1 | - KRW | 0.0% |
2011 Q2 | 10 Billion KRW | 0.0% |
2011 Q3 | 10 Billion KRW | 0.0% |
2011 FY | - KRW | -100.0% |
2011 Q1 | 10 Billion KRW | 0.0% |
2010 Q2 | - KRW | -100.0% |
2010 FY | 10 Billion KRW | 20.63% |
2010 Q1 | 8.14 Billion KRW | -1.73% |
2010 Q4 | 10 Billion KRW | 0.0% |
2010 Q3 | - KRW | 0.0% |
2009 Q2 | 15.56 Billion KRW | -1.44% |
2009 Q3 | 15.42 Billion KRW | -0.87% |
2009 Q1 | 15.79 Billion KRW | -0.49% |
2009 FY | 8.29 Billion KRW | -47.76% |
2009 Q4 | 8.29 Billion KRW | -46.27% |
2008 FY | 15.87 Billion KRW | 0.0% |
2008 Q2 | 8 Billion KRW | 0.0% |
2008 Q4 | 15.87 Billion KRW | 68.34% |
2008 Q3 | 9.42 Billion KRW | 17.85% |
2008 Q1 | 8 Billion KRW | 0.0% |
2007 Q3 | - KRW | 0.0% |
2007 Q4 | - KRW | 0.0% |
2007 FY | - KRW | 0.0% |
2007 Q1 | - KRW | 0.0% |
2007 Q2 | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | -263.404% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 75.469% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -65.91% |
HANDOK Inc. | 123.78 Billion KRW | 59.954% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -10319.172% |
Yuhan Corporation | 60.23 Billion KRW | 17.707% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 69.401% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -48583.499% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 39.572% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -8297.034% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -719.313% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -167.613% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -293.894% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | -3000.265% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | -263.404% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -41318.052% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 59.034% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -54.901% |
JW Holdings Corporation | 20.65 Billion KRW | -139.956% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -234.353% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -65.228% |
JW Pharmaceutical Corporation | 30 Billion KRW | -65.228% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -22538.033% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -8436.777% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -1013.397% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | -263.404% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -160.507% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 46.938% |
JW Pharmaceutical Corporation | 30 Billion KRW | -65.228% |
Yuhan Corporation | 60.23 Billion KRW | 17.707% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | -372.081% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -22.762% |
Suheung Co., Ltd. | 74 Billion KRW | 33.022% |
JW Pharmaceutical Corporation | 30 Billion KRW | -65.228% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -1089.651% |
Korea United Pharm Inc. | 10.96 Billion KRW | -352.164% |
CKD Bio Corp. | 69.43 Billion KRW | 28.608% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -43.366% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -207.35% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -16043.123% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -22538.033% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 31.262% |
Boryung Corporation | 151.7 Billion KRW | 67.326% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 36.876% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -719.313% |
JW Lifescience Corporation | 168 Million KRW | -29405.037% |